



# NAFLDsym<sup>®</sup> 2B


## Predict and Prevent Metabolic Dysfunction-Associated Fatty Liver Disease and MASH

### Key features of NAFLDsym v2B within Julia include:

- ✓ Integration with a modern C++ based graphical user interface (GUI)
- ✓ Integration with the open-source Julia Scientific and Machine Learning (SciML) toolkit to solve simulations efficiently
- ✓ Results viewer that can open previously exported results files
- ✓ Pre-compiled Julia dependencies so users do not need to install a separate Julia environment
- ✓ An interactive console application for editing and appending to existing NAFLDsym QSP model equations

### Sound Science

- ✓ Includes steatosis, lipotoxicity, inflammation, and fibrosis
- ✓ Is used to evaluate the efficacy potential of new drug candidates to treat metabolic dysfunction-associated fatty liver disease (MAFLD) and metabolic dysfunction-associated steatohepatitis (MASH)
- ✓ Can be used to better understand MAFLD/MASH pathophysiology, progression, and treatment mechanisms
- ✓ DILIsym Services has leveraged its long standing expertise in liver physiology and metabolic diseases to develop NAFLDsym
- ✓ Successful simulation of more than 30 MAFLD/MASH compounds or targets within drug development to date



NAFLDsym predicts efficacy via the intersection between exposure, PD, and inter-patient pathophysiologic variability.

### Application Driven

- ✓ Optimize clinical trial protocols by determining favorable dosing paradigms and outcome measurement frequency
- ✓ Evaluate targets and/or specific compounds utilizing key laboratory and/or clinical data describing DMPK and pharmacodynamic characteristics
- ✓ Evaluate combination therapy approaches
- ✓ Compare efficacy in different patient groups (i.e., stratification by NAS, by fibrosis score)
- ✓ Prioritize compounds and targets
- ✓ Can evaluate potential treatments administered to patients also on weight loss drugs